Publications

Below are recent publications from our Faculty.

Viral pathogenesis and antiviral drug discovery and development:

Sun L, Snedeker A, Tang L. A hepatitis B virus RNA-sensing and RNA-editing-dependent reporter system. J Virol. 2025 Oct 10:e0092225. doi: 10.1128/jvi.00922-25. Epub ahead of print. PMID: 41070966.
Block TM, Gotchev D, Du Y. Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past? Antiviral Res. 2025 Oct 9;244:106288. doi: 10.1016/j.antiviral.2025.106288. Epub ahead of print. PMID: 41067564.
Fumuso FG, Clement JA, Todd MJ, O’Connor RM. Tartrolon E rapidly blocks Toxoplasma gondii capacity to invade host cells. Int J Parasitol Drugs Drug Resist. 2025 Aug;28:100591. doi: 10.1016/j.ijpddr.2025.100591. Epub 2025 Apr 14. PMID: 40233443; PMCID: PMC12019577.
Liu H, Rimal H, Lyu J, Shen L, Zhao Q, Chang J, Guo JT. HBV capsid assembly modulators differentially modulate the assembly of wild-type and drug-resistant core protein chimeric nucleocapsids and empty capsids. PLoS Pathog. 2025 Aug 5;21(8):e1013391. doi: 10.1371/journal.ppat.1013391. PMID: 40763308; PMCID: PMC12342251.
Hernández-Lladó P, Meanwell NA, Russell AJ. A Data-Driven Perspective on Bioisostere Evaluation: Mapping the Benzene Bioisostere Landscape with BioSTAR. J Med Chem. 2025 Aug 28;68(16):16921-16939. doi: 10.1021/acs.jmedchem.5c01641. Epub 2025 Aug 5. PMID: 40763221.
Wang F, Gao Z, Chen B, Jiang Z, Renner DM, Li J, Tolufashe G, Du Y, Guo JT, Chang J.Modes of action of a small molecule antiviral compound targeting yellow fever virus NS4B protein. Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2505498122. doi: 10.1073/pnas.2505498122. Epub 2025 May 16.PMID: 403780033
Block T, Guo JT, Zoulim F. et al. New potent HBV replication inhibitors for the management of chronic hepatitis B are needed. Nat Rev Gastroenterol Hepatol 22, 150–151 (2025).
Yang S, Chang J, Zhang J, Guo JT. A Particle Gel Assay for Detection of Intracellular Hepatitis B Virus Subviral Particles in Cultured Cells. Methods Mol Biol. 2024;2837:89-97. doi: 10.1007/978-1-0716-4027-2_8.
Shrestha B, Yang S, Griffith L, Ma J, Wang F, Liu H, Zhao Q, Du Y, Zhang J, Chang J, Guo JT. Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library. Antiviral Res. 2024 Aug;228:105955. doi: 10.1016/j.antiviral.2024.105955
Wen X, Wu X, Sun Y, Zhou J, Guan G, Chen S, Shan S, Ma H, Zhao X, Wang Y, Ou X, You H, Guo JT, Lu F, Jia J. Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB. J Med Vitol. 2024 Jun;96(6):e29606. doi: 10.1002/jmv.29606.
Tang L, Remiszewski S, Snedeker A, Chiang LW, Shenk T. An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity. Antiviral Res. 2024 Jun;226:105888. doi: 10.1016/j.antiviral.2024.105888.
Tolufashe G, Viswanathan U, Kulp J, Guo JT Computational Approaches to Predict Hepatitis B Virus Capsid Protein Mutations That Confer Resistance to Capsid Assembly Modulators.Viruses. 2025 Feb 27;17(3):332. doi: 10.3390/v17030332.PMID: 40143261 Free PMC article.
Li Y, Hwang N, Snedeker A, Lemon SM, Noe D, Sun L, Clement JA, Zhou T, Tang L, Block T, Du Y. “PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro. Bioorg Med Chem Lett. 2024 Apr 1;102:129680. doi: 10.1016/j.bmcl.2024.129680.
Zhao Q, Liu H, Tang L, Wang F, Tolufashe G, Chang J, Guo JT. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res. 2024 Jan;221:105782. doi: 10.1016/j.antiviral.2023.105782.
Zhang T, Zheng H, Lu D, Guan G, Li D, Zhang J, Liu S, Zhao J, Guo JT, Lu F, Chen X. RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation. Signal Transduct Target Ther. 2023 Sep 13;8(1):346. doi: 10.1038/s41392-023-01573-7.
Liu Y, Chen D, Wang Y, Li X, Qiu Y, Zheng M, Song Y, Li G, Song C, Liu T, Zhang Y, Guo JT, Lin H, Zhao X. Characterization of CCoV-HuPn-2018 spike protein-mediated viral entry. .J Virol. 2023 Sep 28;97(9):e0060123. doi: 10.1128/jvi.00601-23.
Hwang N, Wu S, Ban H, Luo H, Ma J, Cheng J, Zhao Q, Laney JA, Du N, Guo J, Suresh M, Shen L, Tolufashe G, Viswanathan U, Kulp J, Lam P, Chang J, Clement JA, Menne S, Guo JT, Du Y. Identification of novel tetrahydroquinoxaline derived phenyl ureas as modulators of the hepatitis B virus nucleocapsid assembly. Eur J Med Chem. 2023 Nov 5;259:115634. doi: 10.1016/j.ejmech.2023.115634.
Hwang, N.; Clement, J. A.; Guo, J-T.; Du, Y. The HBV Capsid Modulators Derived from Sulfamoylbenzamides and Benzamides: An Overview of the Progress of Patents. Med Chem Res 2023, 1345–1368.
Roche KL, Remiszewski S, Todd MJ, Kulp JL 3rd, Tang L, Welsh AV, Barry AP, De C, Reiley WW, Wahl A, Garcia JV, Luftig MA, Shenk T, Tonra JR, Murphy EA, Chiang LW. An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity. J Clin Invest. 2023 Jun 15;133(12):e158978. doi: 10.1172/JCI158978.
Tang L, An P, Zhao Q, Winkler CA, Chang J, Guo JT. Heat Shock Protein Family A Member 1 Promotes Intracellular Amplification of Hepatitis B Virus Covalently Closed Circular DNA. J Virol. 2023 Jan 31;97(1):e0126122. doi: 10.1128/jvi.01261-22.

Precision medicine:.

Lifeng Tian, Xuanmao Jiao, Chenguang Wang, Danni Li, Adam Ertel, Joanna Achinger-Kawecka, Sankar Addya, Raymond E Soccio, Eric R Chen, Balázs Győrffy, Gabriele Di Sante, Zhijiu Zhong, Haidar Alkhafaji, Nina Entcheva, Elyssa M Campbell, Peter A McCue, Andrew V Kossenkov, Rita Pancsa, Peter Tompa, Susan J Clark, Richard G Pestell PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding Oncogene 2025 Jul 26. doi: 10.1038/s41388-025-03492-z.
Zezulinski D, Hoteit MA, Kaplan DE, Simeone A, Zhan T, Doria C, Ahmed FY, Roberts LR, Block T and Sayeed A. Detection of circulating mRNA variants in hepatocellular carcinoma patients using targeted RNAseq. Liver Cancer, March 2025 , in print.
Su YP, Lin SY, Su IJ, Kao YL, Shen SC, Earl JP, Ehrlich GD, Chen CY, Huang W, Su YH, Tsai HW. Characterization of integrated hepatitis B virus DNA harboring pre-S mutations in hepatocellular carcinoma patients with ground glass hepatocytes.J Med Virol. 2024 Jan;96(1):e29348. doi: 10.1002/jmv.29348.

Lin SY, Xia W, Kim AK, Chen D, Schleyer S, Choi L, Wang Z, Hamilton JP, Luu H, Hann HW, Chang TT, Hu CT, Woodard A, Gade TP, Su YH. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma. Sci Rep. 2023 Dec 7;13(1):21585. doi: 10.1038/s41598-023-48500-y.
Kim AK, Lin SY, Wang Z, Luu H, Hamilton JP, Song W, Su YH.Impact of Cell-Debris and Room-Temperature Storage on Urine Circulating Tumor DNA from Hepatocellular Carcinoma. J Mol Diagn. 2023 Dec;25(12):913-920. doi: 10.1016/j.jmoldx.2023.08.006.
Lin SY, Halegoua-DeMarzio D, Block P, Kao YL, Civan J, Shieh FS, Song W, Hann HW, Su YH. Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study. Diagnostics (Basel). 2023 Apr 25;13(9):1537. doi: 10.3390/diagnostics13091537.=
Pan A, Truong TN, Su YH, Dao DY. Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings. Diagnostics (Basel). 2023 Feb 11;13(4):676. doi: 10.3390/diagnostics13040676.

Molecular Oncology and Regeneration Medicine:

GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2.
GBD 2021 Fertility and Forecasting Collaborators.Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 May 18;403(10440):2057-2099. doi: 10.1016/S0140-6736(24)00550-6.
Jiao X, Di Sante G, Casimiro MC, Tantos A, Ashton AW, Li Z, Quach Y, Bhargava D, Di Rocco A, Pupo C, Crosariol M, Lazar T, Tompa P, Wang C, Yu Z, Zhang Z, Aldaaysi K, Vadlamudi R, Mann M, Skordalakes E, Kossenkov A, Du Y, Pestell RG.A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription. 2024 Jan 8;13(1):4. doi: 10.1038/s41389-023-00502-1.
Hamid R, Alaziz M, Mahal AS, Ashton AW, Halama N, Jaeger D, Jiao X, Pestell RG.The Role and Therapeutic Targeting of CCR5 in Breast Cancer. 2023 Sep 8;12(18):2237. doi: 10.3390/cells12182237.PMID: 37759462
Li Z, Jiao X, Robertson AG, Di Sante G, Ashton AW, DiRocco A, Wang M, Zhao J, Addya S, Wang C, McCue PA, South AP, Cordon-Cardo C, Liu R, Patel K, Hamid R, Parmar J, DuHadaway JB, Jones SJM, Casimiro MC, Schultz N, Kossenkov A, Phoon LY, Chen H, Lan L, Sun Y, Iczkowski KA, Rui H, Pestell RG. The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses. 2023 Jun;42(22):1857-1873. doi: 10.1038/s41388-023-02668-9.
Lü J, Zhao Q, Guo Y, Li D, Xie H, Liu C, Hu X, Liu S, Hou Z, Wei X, Zheng D, Pestell RG, Yu Z.Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling. J Exp Clin Cancer Res. 2023 Apr 20;42(1):93. doi: 10.1186/s13046-023-02665-6.

Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Nevalainen MT, Pestell RG, Fuchs SY, Mitchell EP, Rui H. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precis Oncol. 2023 Jan;7:e2100498. doi: 10.1200/PO.21.00498.

Publications

Support Us

Social

Location

Email Us

Phone Us